European Medicines Agency

Europe’s medicines regulator on Friday recommended granting a marketing authorization to Biogen’s drug for the deadly and progressive neurodegenerative disease known as amyotrophic lateral sclerosis (ALS).


Pharmaceutical companies last year launched new U.S. drugs at prices 35% higher than in 2022, reflecting in part the industry’s embrace of expensive therapies for rare diseases like muscular dystrophy, a Reuters analysis found.


The FDA has granted Priority Review to Sanofi and Regeneron’s supplemental Biologics License Application seeking to expand its blockbuster antibody therapeutic Dupixent (dupilumab) into chronic obstructive pulmonary disease, the companies announced Friday.

India’s drugmakers look to tap weight-loss market with versions of Wegovy Published: Feb 23, 2024 By Tristan Manalac BioSpace Indian pharma companies have started developing their own versions of Novo […]

Frontier Medicines on Thursday closed its oversubscribed $80 million Series C funding round,  which it will use to advance its potentially first-in-class next-generation KRAS blocker FMC-376.

San Francisco-based Rigel Pharmaceuticals on Thursday announced it will acquire the U.S. rights to Blueprint Medicines’ FDA-approved non-small cell lung cancer drug Gavreto (pralsetinib).